Background -Dabigatran reduces ischemic stroke compared to warfarin; however, given the
peri ri-p -p pro ro roce ce cedu du dura ra r l ma ma majo j r bleeding between patients s r r rec ec e eiving dabigatran-n-11 11 110 (3.8%) or dabigatran- The RE-LY trial demonstrated that dabigatran is well-tolerated and that compared to warfarin, dabigatran 150 BID is more effective at preventing stroke and systemic embolism with a similar risk of major bleeding, while dabigatran 110 BID is associated with a lower risk of major bleeding and a similar rate of stroke and systemic embolism 1 . However, as the anticoagulant effect of dabigatran is currently difficult to precisely measure and the drug does not yet have a specific antidote, there is concern that dabigatran may increase the risk of bleeding in patients undergoing invasive procedures, particularly if performed on an emergency basis 2;3 .
Each year, approximately 10% of all patients receiving oral anticoagulants require treatment interruption for surgery or an invasive procedure 4 . Given the long and variable halflife of vitamin K antagonists, guidelines recommend that patients discontinue warfarin 5 days before major procedures and that those at moderate or high risk of thromboembolic events receive peri-operative bridging with low-molecular-weight heparin [4] [5] [6] ; however, this is associated with additional costs, inconvenience and risks 4;7;8 . The more predictable anticoagulant effect and shorter half-life of dabigatran has the potential to simplify the perioperative management of anticoagulation but the risk of peri-operative bleeding and thrombotic events with dabigatran has not been reported and the best strategy for peri-operative management of dabigatran is uncertain. The RE-LY trial captured extensive data on anticoagulant discontinuation for surgery or invasive procedure 9 and can help inform both of these issues.
Methods
The main results of the RE-LY trial have previously been published 1 . During the course of the study all patients who required surgery, dental procedures, cardiac catheterization or invasive diagnostic procedures (including percutaneous biopsy, peripheral angiography and similar procedures) had details of the peri-operative management of their anticoagulation prospectively ife of vitamin K antagonists, guidelines recommend that patients discontinue wa wa arf rfar ar a in n n 5 5 5 d d day ay ays s before major procedures and that those at moderate or high risk of thromboembolic events e ece ce eiv iv ive e e pe pe eri ri ri-o -o ope era ra rat ti tiv ve bridging with low-molecu u ula la l r r--weight hepar rin in i 4-6 6 ; ; h ho however, this is asso o oci c ated wit th h h ad ad addi diti i tion on nal al al c c cos os ost ts ts, , in in nc co con nv ve e enie enc nc ce an n nd d d risk sk sks s 4;7 4;7 ;7;8 8 8 . T T The he e m mo or re e pr pred ed edic icta ta abl bl ble e e an nti ti tico co oag ag agul ulan an ant t t ef eff f fec ct ct a and nd nd s sho hort rt rter er r h h ha a alf lf lf-l -li if fe e of of of d d dab ab abig ig iga at atr ra ran n n ha ha has s s t th the e e po po ote e ent nt ntia ia al t to o s sim im impl pl plif if fy y y th the e e pe pe eri ri--operative ma ana na nage ge g me me ment nt nt o o of an an anti ti tico o oag ag agul ul ulat a io io ion n n bu bu but t t th th he e e ri ri risk sk sk o of f f pe pe peri ri i-o -o ope pe pera a ati ti tive ve ve b b ble le leed ed e in n ng g g an an and d Table 1) . In all cases, dabigatran was re-started post-procedure once adequate hemostasis had been achieved.
For this analysis, the peri-procedural period was defined as lasting from 7 days prior to the procedure until 30 days after. All outcomes were defined using the same criteria that were used in the main RE-LY trial 9 . Bleeding outcomes of interest included: major bleeding, fatal bleeding, bleeding requiring surgery and all-cause bleeding. Major bleeding, was the primary bleeding outcome for all analyses and was defined as a reduction in hemoglobin of at least 20 g per liter, transfusion of at least 2 units of blood or symptomatic bleeding into a critical area or organ 1 . Thrombo-embolic complications included ischemic stroke, systemic embolism, myocardial infarction, pulmonary embolism and death. The primary analysis was limited to the first surgery or procedure for each patient during the course of the study, to avoid the influence of intra-patient correlation for subsequent events; however, data are also presented for all bleeding (such as cardiac, abdominal and neurosurgery or procedures requiring s sp pi pina n n l l anesthesia), dabigatran was to be discontinued 2 to 5 days prior to surgery, depending on renal fu unc nc cti ti tio on on ( ( (Ta Ta Tab b ble e 1 1 1) ). ). In all cases, dabigatran was s s re re r --started post-pr pr proced ed dur ur ure e once adequate h he hem mo mostasis had ad b b bee en n a a achi hi hiev ev e ed ed ed.
F For or r t t thi h his s a an ana al alys ys sis s, , , th the pe pe p ri ri ri-p -p -pr ro roce ce edu du dura ra ral l l pe pe peri rio od od wa wa as s de de def f fine ne ned d as s s l l las as a t t ting ng g fr fr from om m 7 7 d d da ay ays s s pr pr rio ior r r to o o he procedur re e un un unti ti il l l 30 30 30 d d day ays s s af af afte e er. r. r Al Al All ou ou outc tc tcom om omes es es we we were re re d def ef efin in ned ed ed u u usi si sing ng g t t he he he s s sam am ame e cr cr crit it iter er eria ia ia t t hat were surgeries performed during the trial. All cases of peri-procedural stroke, systemic embolism and myocardial infarction were reviewed to exclude outcomes where the procedure or surgery was performed secondary to a clinical event (e.g., embolectomy to treat systemic embolism).
The rate of bleeding and thrombotic complications in patients receiving warfarin was compared with the rate in those receiving dabigatran 110 mg bid or dabigatran 150 mg bid was presented using the relative risk and compared using a chi-squared test. Sub-group analyses were pre-specified in the analysis plan to evaluate the outcome of major bleeding in patients having elective vs. urgent surgery; major vs. minor surgery and for those whose dabigatran was managed using the original vs. amended protocol. The effect of these sub-groups was evaluated using an interaction p-value. The effect of the timing of anticoagulant interruption on major bleeding was a post-hoc analysis and was evaluated using the Cochran-Armitage test for trend.
A secondary analysis of major bleeding was done using data from all procedures performed during the study, including subsequent procedures for patients who had more than one. This analysis involved fitting a marginal logistic regression model with generalized estimating equation method) and the treatment effect presented using the odds ratio.
Results
During a mean follow-up of 2 years, 4591 patients in the RE-LY trial had oral anticoagulant therapy interrupted at least once to have surgery or another invasive procedure. This represented 24.7% of patients assigned to dab-110, 25.4% on dab-150 and 25.9% on warfarin, p=0.34. The baseline characteristics of patients having interruption of oral anticoagulant therapy for surgery or procedures were similar between the three treatment groups ( Table 2 ). The most common surgeries and procedures were: pacemaker or defibrillator insertion (10.3%), dental procedures (10.0%), diagnostic procedures (10.0%), cataract removal (9.3%), colonoscopy using an interaction p-value. The effect of the timing of anticoagulant interruptio io on on on o m m maj aj ajor or or f bleeding was a post-hoc analysis and was evaluated using the Cochran-Armitage test for trend.
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(8.6%) and joint replacement (6.2%), with other types of surgery each accounting for a smaller proportion of cases ( Table 2) . Peri-procedural bridging with intra-venous heparin or low molecular weight heparin was used in 15.3% of patients assigned to dabigatran 110 mg twicedaily, 17.0% of patients assigned to dabigatran 150 mg twice daily and 28.5% of patients assigned to warfarin (p<0.001). Vitamin K was given peri-operatively in 99 patients (2.2%):
9/1487 on dabigatran 110 mg twice-daily, 18/1546 on dabigatran 150 mg twice-daily and 72/1558 on warfarin. Fresh-frozen plasma was given to 1.5% of patients: 20/1487 on dabigatran 110 mg twice-daily, 17/1546 on dabigatran 150 mg twice-daily and 32/1558 on warfarin.
There was no significant difference in the incidence of peri-operative major bleeding between patients receiving warfarin (4.6%) compared with dabigatran 110 mg twice-daily (3.8%) and dabigatran 150 mg twice-daily (5.1%); Table 3 . The results for all other bleeding outcomes, including fatal bleeding, bleeding requiring re-operation, bleeding requiring transfusion of red blood cells and minor bleeding were consistent with the primary outcome of major bleeding ( Table 3 ). The incidences of stroke and all other thromboembolic complications, including cardiovascular death, systemic embolism, myocardial infarction or pulmonary embolism, were low and not significantly different between randomized treatment arms ( Table 3) .
Repeating this analysis, including initial and all subsequent procedures performed during the RE-LY trial, there were 2485 procedures performed in patients receiving dabigatran 110 mg twice-daily, 2635 in those receiving dabigatran 150 twice-daily and 2517 in patients receiving warfarin. After adjusting for correlated outcomes, the results for major bleeding remained similar to the analysis examining only first procedures, both for dabigatran 110 mg twice-daily (OR=0.88; 95% CI: 0.63-1.12, p=0.23) and dabigatran 150 mg twice-daily (OR=0.92; 95% CI: between patients receiving warfarin (4.6%) compared with dabigatran 110 mg tw w wic ice-e e da da dail il ily y y 3.8%) and dabigatran 150 mg twice-daily (5.1%); Table 3 Among patients assigned to warfarin, 7.1% of surgery was classified as urgent, compared to 4.2% of patients assigned to dabigatran 110 mg twice-daily and 9.1% of patients assigned to dabigatran 150 mg twice-daily ( Table 4) . Compared to those having elective surgery, the incidence of major bleeding for patients in each treatment arm who had urgent surgery were 5 to 6-fold higher ( Table 4 , p<0.001 for all treatment arms). Similarly, the incidence of ischemic stroke or systemic embolism was more than four times greater among patients in all treatment groups who underwent urgent surgery: dabigatran 110 mg twice-daily (2.8% vs. 0.3%);
dabigatran 150 mg twice-daily (1.4% vs. 0.4%) and warfarin (1.8% vs. 0.4%). However; there were no significant differences in these outcomes between treatment groups when separately considering elective or urgent surgery ( Table 4) .
Accurate procedural durations were available for 28% of all surgery or procedures, which were classified as major in 53% of cases. In all three treatment arms, major bleeding was more common with major compared to minor surgery: dabigatran 110 mg twice-daily: 6.1% vs. During the course of the RE-LY trial, the suggested approach for the pre-procedural management of dabigatran was changed from discontinuation 24 hours pre-procedurally in all cases, to an algorithm based on renal function for patients having surgery with an anticipated were no significant differences in these outcomes between treatment groups whe en n n se se s pa pa para ra rate te tely ly ly considering elective or urgent surgery ( Table 4) .
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A separate analysis was done to determine the impact of the timing of pre-operative study medication interruption on the rate of major bleeding and the influence of baseline renal function on this risk ( Among surgeries or procedures that were completed within 48 hours of study drug discontinuation, they were classified as urgent in 7.9% of patients receiving dabigatran 110 mg bid, 10.5% of patients receiving dabigatran 150 mg bid and 28.7% of patients receiving warfarin, p<0.0001. Compared to warfarin, both doses of dabigatran were associated with a lower risk of peri-operative bleeding when study medication was discontinued within 48 hours prior to surgery ( Table 5) .
Discussion
This study compared the peri-procedural use of dabigatran to warfarin and includes data from on this risk (Table 5) . Among patients assigned to dabigatran 110 mg twice-dail il ly, y t t the he e l l las as ast t t do do dose s This is reassuring, given the lack of a widely available test to precisely measure the anticoagulant effect of dabigatran and the lack of a direct reversing agent 2 and the concern that dabigatran may increase the risk of bleeding complications related to surgery or procedures, especially those that are urgent 3 . This analysis also highlights how commonly anticoagulated patients with atrial fibrillation require invasive procedures or surgery, as this occurred in approximately one-quarter of patients in RE-LY 1 over a two-year period.
The RE-LY trial was not specifically designed to evaluate peri-procedural bleeding and no formal statistical power was calculated a-priori for this outcome. However, the randomized design of RE-LY and the large number of patients included in this analysis should reliably exclude large differences in peri-procedural bleeding outcomes between the anticoagulant strategies that were evaluated. Using the confidence interval approach and examining only outcomes for first procedures, we can conclude with 95% confidence that compared to warfarin, the use of dabigatran 110 BID does not increase the rate of peri-procedural major bleeding by more than a 17% and dabigatran 150 BID does not increase major bleeding by more than 49%.
When one considers all 7637 treatment interruptions for procedures in RE-LY, we have 95% confidence to conclude that the rate of peri-procedural major bleeding is not increased by more than 12% with dabigatran 110 BID and 22% with dabigatran 150 BID. Further, our results in those patients undergoing procedures is consistent with the overall results of the RE-LY trial 1 and this provides additional confidence that our findings of similar rates of major bleeding between treatment groups is accurate.
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One of the key advantages of dabigatran compared to warfarin in patients undergoing invasive procedures is its short half-life, which enables dabigatran to be continued in many patients until 24 to 48 hours before the procedure; thereby minimizing the risk of thromboembolic complications, the costs and complications of heparin bridging, while still ensuring adequate hemostasis at the time of surgery 2;7;8 . In RE-LY, nearly half of all patients treated with dabigatran had surgery within 48 hours of stopping oral anticoagulation; a rate more than four times higher than among patients receiving warfarin. When surgery or a procedure was performed during this short period, dabigatran-treated patients had a substantially lower rate of major bleeding compared to those receiving warfarin, although this is likely explained by the higher proportion of non-urgent surgery that was completed in dabigatran-treated patients. There was very likely a greater tendency among dabigatran-treated patients compared to warfarintreated patients to perform surgery within 24-48 hours among patients perceived to be at lower risk of bleeding and to wait > 72 hours among patients with a higher risk. There was rather limited use of vitamin K and fresh-frozen plasma among warfarin-treated patients. Although physicians express a desire for specific reversing agents, fewer than 5% of warfarin-treated patients in the RE-LY trial received vitamin K and 2% received fresh-frozen plasma before undergoing an invasive procedure. By contrast, the short half-life of dabigatran facilitated rapid restoration of normal hemostasis, obviating the need for an antidote in the majority of patients.
The optimal timing of discontinuation of dabigatran before surgery is influenced by renal function and the bleeding risk of the surgery 10;11 . Dabigatran is 80% renally excreted; in patients with a creatinine clearance >80 mL/min, it has an estimated half-life of 13 hours (range 11-22 hours), in those with a clearance of 51 to 80 mL/min the half-life is 15 hours (12 to 34) and in those with a clearance of 31 to 50 mL/min the half-life is 18 hours (13 to 23) [12] [13] [14] . For higher proportion of non-urgent surgery that was completed in dabigatran-treated ed d p pat at a ie ie ent nt nts s. s. T T Th he here was very likely a greater tendency among dabigatran-treated patients compared to warfarinr rea ea ate te ted d d pa pa ati ti tien en ents t to o o p pe perform surgery within 24-48 8 h h ho ou urs among pat tie ie i nts s pe pe perc r eived to be at lower i i isk k k o of bleeding ng a an n nd t to o o wa wa wait it it > > > 7 7 72 2 ho ho hour ur u s s a a amon ng g g pat t tie e ents s s w w wit ith h h a a a hi high gh her r r ris i i k k k. T T The he here re w w was as s r ra a athe he her r i imi mi mite te ed d d us use e e of of of v vit it tam m min in n K K K a and nd d f f re re esh sh sh-f -f -fro roz ze zen n n pl pl plas s sma ma ma a amo mo mong ng ng w w war ar rfa fa fari ri in-n--tr tr trea ea at ted d d pa pa ati tien en e ts ts s. . A Alt lt tho ho oug ug gh h physicians exp xp xpre re ress ss s a a a d d des es sire e e fo fo for sp sp spec ec ecif if i ic c c r r rev ev ever er ersi si sing ng ng a a age ge gent nts, s, s, f f few ew ewer er er th th than n n 5 5 5% % % of of of w w war ar arfa fa fari ri r n-n-n t t reated patients undergoing procedures that are associated with a "standard" risk of bleeding (e.g. hernia repair) dabigatran should be stopped for 2-3 half-lives before the procedure as this will allow drug levels to fall to 25% or lower of steady state trough levels 10;11 . For procedures that are associated with a high risk of bleeding (e.g. cardiac surgery) or where normal hemostasis is critical (e.g. neurosurgery), dabigatran is recommended to be stopped for 4-5 half-lives before surgery and an activated partial thromboplastin time (aPTT) or thrombin time (TT) should ideally be performed before surgery to ensure that the level has returned to normal 10;11 . The Hemoclot test, calibrated for dabigatran, is available outside the USA and will be useful once it becomes more widely available as it provides a highly accurate estimation of dabigatran concentration 11 . Although this analysis from RE-LY did not demonstrate a reduction in major peri-operative bleeding with introduction of the more conservative protocol for the pre-operative management of dabigatran ( Table 1 ) compared to simply withholding for 24 hours in all patients, the majority of patients included in these analyses underwent surgery with a "standard" risk of bleeding so the comparative analysis is under-powered ( Table 2) . Furthermore, the amended protocol was introduced relatively late in the course of the trial and was tested in relatively small numbers of patients. Nevertheless, the amended protocol recommendations take into account what we know about the pharmacology of dabigatran 11-14 and we support their adoption for the management of dabigatran-treated patients undergoing an invasive procedure ( Table 1) .
Conclusions
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